MX2021007369A - Combinacion farmaceutica de anticuerpos anti ceacam6 y tim3. - Google Patents

Combinacion farmaceutica de anticuerpos anti ceacam6 y tim3.

Info

Publication number
MX2021007369A
MX2021007369A MX2021007369A MX2021007369A MX2021007369A MX 2021007369 A MX2021007369 A MX 2021007369A MX 2021007369 A MX2021007369 A MX 2021007369A MX 2021007369 A MX2021007369 A MX 2021007369A MX 2021007369 A MX2021007369 A MX 2021007369A
Authority
MX
Mexico
Prior art keywords
pharmaceutical combination
component
tim3 antibodies
ceacam6
anti ceacam6
Prior art date
Application number
MX2021007369A
Other languages
English (en)
Inventor
Mark Trautwein
Jörg Willuda
Rienk Offringa
Philipp Beckhove
Hans-Henning Böhm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2021007369A publication Critical patent/MX2021007369A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invención se refiere a combinaciones de por lo menos dos componentes, un componente A y un componente B, siendo el componente A un anticuerpo anti-CEACAM6 TPP-3310 y siendo el componente B un anticuerpo anti-TIM-3, preferentemente cobolimab, MBG-453, BMS-986258, Sym-023, LY-3321367 o INCAGN-2390.
MX2021007369A 2018-12-19 2019-12-12 Combinacion farmaceutica de anticuerpos anti ceacam6 y tim3. MX2021007369A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18214059 2018-12-19
PCT/EP2019/084849 WO2020126808A1 (en) 2018-12-19 2019-12-12 Pharmaceutical combination of anti ceacam6 and tim3 antibodies

Publications (1)

Publication Number Publication Date
MX2021007369A true MX2021007369A (es) 2021-07-15

Family

ID=65009547

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007369A MX2021007369A (es) 2018-12-19 2019-12-12 Combinacion farmaceutica de anticuerpos anti ceacam6 y tim3.

Country Status (12)

Country Link
US (1) US20220089721A1 (es)
EP (1) EP3897844B1 (es)
JP (1) JP2022513246A (es)
KR (1) KR20210104704A (es)
CN (1) CN113164778A (es)
AU (1) AU2019407364A1 (es)
BR (1) BR112021007968A2 (es)
CA (1) CA3123735A1 (es)
IL (1) IL283746B1 (es)
MX (1) MX2021007369A (es)
SG (1) SG11202104518WA (es)
WO (1) WO2020126808A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022340907A1 (en) 2021-09-02 2024-03-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Anti-cecam6 antibodies with reduced side-effects

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
DE8808645U1 (es) 1988-07-06 1988-08-25 Hofer, Daniel, 7730 Villingen-Schwenningen, De
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US10131712B2 (en) * 2012-08-14 2018-11-20 Ibc Pharmaceuticals, Inc. Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
EP2981281B1 (en) * 2013-04-03 2020-07-15 IBC Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JOP20200096A1 (ar) * 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015126548A1 (en) * 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
CN107743495B (zh) * 2015-03-23 2021-05-14 拜耳制药股份公司 抗ceacam6抗体及其用途
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
CN109451741B (zh) 2016-04-12 2023-07-28 法国施维雅药厂 抗tim-3抗体及组合物
WO2017205721A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
WO2017210058A1 (en) * 2016-06-01 2017-12-07 Ibc Pharmaceuticals, Inc. Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors
PE20190418A1 (es) 2016-07-14 2019-03-19 Bristol Myers Squibb Co Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
JOP20190013A1 (ar) 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
JP7118073B2 (ja) 2017-01-09 2022-08-15 テサロ， インコーポレイテッド 抗ｔｉｍ－３抗体を用いてがんを処置する方法
CN112996814A (zh) * 2018-11-14 2021-06-18 拜耳公司 用于治疗癌症的抗ceacam6和抗pd-1或抗pd-l1抗体的药物组合

Also Published As

Publication number Publication date
BR112021007968A2 (pt) 2021-09-08
CN113164778A (zh) 2021-07-23
IL283746B1 (en) 2024-04-01
IL283746A (en) 2021-07-29
WO2020126808A1 (en) 2020-06-25
CA3123735A1 (en) 2020-06-25
KR20210104704A (ko) 2021-08-25
JP2022513246A (ja) 2022-02-07
US20220089721A1 (en) 2022-03-24
SG11202104518WA (en) 2021-05-28
EP3897844C0 (en) 2023-11-15
EP3897844A1 (en) 2021-10-27
EP3897844B1 (en) 2023-11-15
AU2019407364A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
PH12019502275A1 (en) Anti-ilt4 antibodies and antigen-binding fragments
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
PH12018501042A1 (en) Antibodies and antibody fragments for site-specific conjugation
MX2019014265A (es) Tratamientos conjuntos triples con anticuerpos.
PH12020550408A1 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
MX2018008592A (es) Anticuerpos monoclonales humanizados inmunoestimulantes contra interleucina-2 humana, y proteinas de fusion de los mismos.
IL280467A (en) Antibody constructs for CLDN18.2 and CD3
NZ751246A (en) Anti-tim-3 antibodies and use thereof
MX2019012953A (es) Anticuerpo biespecifico contra ox40 y ctla-4.
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
SG10201901057UA (en) Anti-pd-l1 antibodies
EP4299073A3 (en) Humanized and affinity matured antibodies to fcrh5 and methods of use
PH12018501611A1 (en) Antigen binding proteins thant bind pd-l1
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
PH12019500552A1 (en) Antibody specifically binding to pd-1 and functional fragment thereof
AU2018230657A8 (en) Anti-C5 antibodies and uses thereof
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
WO2019094595A3 (en) Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
MX2020002241A (es) Anticuerpos anti-tm4sf y métodos de uso de los mismos.
SG10201801219VA (en) Anti-HER2 Antibodies
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2021002710A (es) Anticuerpos anti-c5 humanizados y usos de los mismos.
AU2018338423A1 (en) Novel anti-HLA-A2 antibodies and uses thereof
MX2021002750A (es) Anticuerpos anti-tnfrsf9 y usos de los mismos.
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.